Pathophysiology of cyclooxygenases in cardiovascular homeostasis

Rani S. Sellers, Z. A. Radi, N. K. Khan

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cyclooxygenase (COX) catalyzes the conversion of arachidonic acid into prostaglandin H2 (PGH2), which is subsequently converted to the prostanoids PGE2, PGI2, PGF, and thromboxane A2. COX has 2 distinct membrane-anchored isoenzymes: COX-1 and COX-2. COX-1 is constitutively expressed in most normal tissues; COX-2 is highly induced by proinflammatory mediators in the setting of inflammation, injury, and pain. Inhibitors of COX activity include conventional nonselective nonsteroidal anti-inflammatory drugs and selective nonsteroidal anti-inflammatory drugs, such as COX-2 inhibitors. The adverse effects of COX inhibitors on the cardiovascular system have been addressed in the last few years. In general, COX inhibitors have many effects, but those most important to the cardiovascular system can be direct (through the effects of prostanoids) and indirect (through alterations in fluid dynamics). Despite reports of detrimental human cardiovascular events associated with COX inhibitors, short, long, and lifetime preclinical toxicology studies in rodents and nonrodents have failed to identify these risks. This article focuses on the expression and function of COX enzymes in normal and pathologic conditions of the cardiovascular system and discusses the cardiovascular pathophysiologic complications associated with COX inhibition.

Original languageEnglish (US)
Pages (from-to)601-613
Number of pages13
JournalVeterinary Pathology
Volume47
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Cyclooxygenase Inhibitors
prostaglandin synthase
Prostaglandin-Endoperoxide Synthases
pathophysiology
homeostasis
Homeostasis
Cyclooxygenase 2
Cardiovascular System
Cyclooxygenase 1
Prostaglandins
Anti-Inflammatory Agents
Prostaglandin H2
Thromboxane A2
Dinoprost
Cyclooxygenase 2 Inhibitors
cardiovascular system
Epoprostenol
Hydrodynamics
Dinoprostone
Arachidonic Acid

Keywords

  • Cardiovascular
  • COX-1
  • COX-2
  • Cyclooxygenase
  • Nonselective nonsteroidal anti-inflammatory drugs
  • NSAIDs
  • Selective nonsteroidal anti-inflammatory drugs

ASJC Scopus subject areas

  • veterinary(all)
  • Medicine(all)

Cite this

Pathophysiology of cyclooxygenases in cardiovascular homeostasis. / Sellers, Rani S.; Radi, Z. A.; Khan, N. K.

In: Veterinary Pathology, Vol. 47, No. 4, 2010, p. 601-613.

Research output: Contribution to journalArticle

Sellers, Rani S. ; Radi, Z. A. ; Khan, N. K. / Pathophysiology of cyclooxygenases in cardiovascular homeostasis. In: Veterinary Pathology. 2010 ; Vol. 47, No. 4. pp. 601-613.
@article{ef5832e80e654840b3d12dacf45a18b6,
title = "Pathophysiology of cyclooxygenases in cardiovascular homeostasis",
abstract = "Cyclooxygenase (COX) catalyzes the conversion of arachidonic acid into prostaglandin H2 (PGH2), which is subsequently converted to the prostanoids PGE2, PGI2, PGF2α, and thromboxane A2. COX has 2 distinct membrane-anchored isoenzymes: COX-1 and COX-2. COX-1 is constitutively expressed in most normal tissues; COX-2 is highly induced by proinflammatory mediators in the setting of inflammation, injury, and pain. Inhibitors of COX activity include conventional nonselective nonsteroidal anti-inflammatory drugs and selective nonsteroidal anti-inflammatory drugs, such as COX-2 inhibitors. The adverse effects of COX inhibitors on the cardiovascular system have been addressed in the last few years. In general, COX inhibitors have many effects, but those most important to the cardiovascular system can be direct (through the effects of prostanoids) and indirect (through alterations in fluid dynamics). Despite reports of detrimental human cardiovascular events associated with COX inhibitors, short, long, and lifetime preclinical toxicology studies in rodents and nonrodents have failed to identify these risks. This article focuses on the expression and function of COX enzymes in normal and pathologic conditions of the cardiovascular system and discusses the cardiovascular pathophysiologic complications associated with COX inhibition.",
keywords = "Cardiovascular, COX-1, COX-2, Cyclooxygenase, Nonselective nonsteroidal anti-inflammatory drugs, NSAIDs, Selective nonsteroidal anti-inflammatory drugs",
author = "Sellers, {Rani S.} and Radi, {Z. A.} and Khan, {N. K.}",
year = "2010",
doi = "10.1177/0300985810364389",
language = "English (US)",
volume = "47",
pages = "601--613",
journal = "Veterinary Pathology",
issn = "0300-9858",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Pathophysiology of cyclooxygenases in cardiovascular homeostasis

AU - Sellers, Rani S.

AU - Radi, Z. A.

AU - Khan, N. K.

PY - 2010

Y1 - 2010

N2 - Cyclooxygenase (COX) catalyzes the conversion of arachidonic acid into prostaglandin H2 (PGH2), which is subsequently converted to the prostanoids PGE2, PGI2, PGF2α, and thromboxane A2. COX has 2 distinct membrane-anchored isoenzymes: COX-1 and COX-2. COX-1 is constitutively expressed in most normal tissues; COX-2 is highly induced by proinflammatory mediators in the setting of inflammation, injury, and pain. Inhibitors of COX activity include conventional nonselective nonsteroidal anti-inflammatory drugs and selective nonsteroidal anti-inflammatory drugs, such as COX-2 inhibitors. The adverse effects of COX inhibitors on the cardiovascular system have been addressed in the last few years. In general, COX inhibitors have many effects, but those most important to the cardiovascular system can be direct (through the effects of prostanoids) and indirect (through alterations in fluid dynamics). Despite reports of detrimental human cardiovascular events associated with COX inhibitors, short, long, and lifetime preclinical toxicology studies in rodents and nonrodents have failed to identify these risks. This article focuses on the expression and function of COX enzymes in normal and pathologic conditions of the cardiovascular system and discusses the cardiovascular pathophysiologic complications associated with COX inhibition.

AB - Cyclooxygenase (COX) catalyzes the conversion of arachidonic acid into prostaglandin H2 (PGH2), which is subsequently converted to the prostanoids PGE2, PGI2, PGF2α, and thromboxane A2. COX has 2 distinct membrane-anchored isoenzymes: COX-1 and COX-2. COX-1 is constitutively expressed in most normal tissues; COX-2 is highly induced by proinflammatory mediators in the setting of inflammation, injury, and pain. Inhibitors of COX activity include conventional nonselective nonsteroidal anti-inflammatory drugs and selective nonsteroidal anti-inflammatory drugs, such as COX-2 inhibitors. The adverse effects of COX inhibitors on the cardiovascular system have been addressed in the last few years. In general, COX inhibitors have many effects, but those most important to the cardiovascular system can be direct (through the effects of prostanoids) and indirect (through alterations in fluid dynamics). Despite reports of detrimental human cardiovascular events associated with COX inhibitors, short, long, and lifetime preclinical toxicology studies in rodents and nonrodents have failed to identify these risks. This article focuses on the expression and function of COX enzymes in normal and pathologic conditions of the cardiovascular system and discusses the cardiovascular pathophysiologic complications associated with COX inhibition.

KW - Cardiovascular

KW - COX-1

KW - COX-2

KW - Cyclooxygenase

KW - Nonselective nonsteroidal anti-inflammatory drugs

KW - NSAIDs

KW - Selective nonsteroidal anti-inflammatory drugs

UR - http://www.scopus.com/inward/record.url?scp=77954920270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954920270&partnerID=8YFLogxK

U2 - 10.1177/0300985810364389

DO - 10.1177/0300985810364389

M3 - Article

VL - 47

SP - 601

EP - 613

JO - Veterinary Pathology

JF - Veterinary Pathology

SN - 0300-9858

IS - 4

ER -